MTSR Company Profile and Key Details

Wall Street analysts project EPS growth of 36.16% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $77.00 to $50.00. The high target offers 9.22% upside. The low target suggests -29.08% downside. The mean target is $61.33. This offers -13.01% upside. Metsera, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 98.21%. The prior quarter beat by 0.29%. Over the last six quarters, Apple has recorded several small beats. These include 340.0% in March 26, 2025.

Short-term trend indicators are bearishly aligned (SMA20 12.5%, SMA50 33.58%, SMA200 101.93%). The stock’s 14-day RSI is 62.09 (firm momentum), while the ATR of 3.56 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.93% below its high and over 473.17% above its low.

Metsera, Inc. has 105.38 million shares outstanding. The public float is 64.78 million shares, elevated short interest at 9.60% of float. This equals 4.77 million shares. The short ratio is 2.52 days. Institutional investors hold 102.38% of the float. Insiders own 17.71%.

Metsera, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.33. This means the shares are trading above this model’s fair value.

Metsera, Inc. (NASDAQ:MTSR) closed at $70.50 USD, losing -$0.25 (-0.35%) from the previous close of $70.75. The stock is currently mid-range between its 52-week high and low $12.30 and $83.86. With a market capitalization of about $7.43 billion, Metsera, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.70). Key stats such as the average daily volume over the past year has been around 3.50 million shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Metsera, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Whitten Bernard, the company employs approximately 93 people and listed since January 31, 2025. Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides.

Our AI price prediction model suggests that Metsera, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 26.06%, with price expected at $88.87 by November 27, 2025, within a range of $83.73 to $93.93 3-Month Outlook: Projected rise of 138.18%, reaching $167.92 by February 11, 2026, with a range of $167.05 to $168.83. 1-Year Outlook: Projected gain of 60.88%, with price at $113.42 by November 13, 2026, within a range of $110.67 to $115.07.

currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Metsera, Inc. trading at a premium to the broader market with a P/E of -23.34. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $57.17, suggesting -18.91% downside. Our AI forecast model points to short-term strength (26.06% over two weeks), a medium-term rise (138.18% over three months), and a longer-term gain (60.88% over one year), with expected trading ranges indicating moderate volatility.

Metsera, Inc. trades at a P/E ratio of -23.34, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 21.96 reflecting a rich premium to book value. The P/FCF stands at -32.08, also below market averages. Compared to sector medians, Metsera, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.